| For: | Mancuso A. Hepatocellular carcinoma in thalassemia: A critical review. World J Hepatol 2010; 2(5): 171-174 [PMID: 21160991 DOI: 10.4254/wjh.v2.i5.171] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v2/i5/171.htm |
| Number | Citing Articles |
| 1 |
Hassan M. Moukhadder, Racha Halawi, Maria Domenica Cappellini, Ali T. Taher. Reply to Management of hepatocellular carcinoma in thalassemia and importance of the human factor. Cancer 2017; 123(6) doi: 10.1002/cncr.30550
|
| 2 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2017; doi: 10.1007/978-3-319-26956-6_165
|
| 3 |
Sandeep Soni. Gene therapies for transfusion dependent β‐thalassemia: Current status and critical criteria for success. American Journal of Hematology 2020; 95(9) doi: 10.1002/ajh.25909
|
| 4 |
Hassan M. Moukhadder, Racha Halawi, Maria Domenica Cappellini, Ali T. Taher. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. Cancer 2017; 123(5) doi: 10.1002/cncr.30462
|
| 5 |
A. Mancuso. Letter: hepatocellular carcinoma in thalassaemia – emerging issues and challenges for liver transplant. Alimentary Pharmacology & Therapeutics 2014; 40(11-12) doi: 10.1111/apt.12989
|
| 6 |
Said Y. Mohamed. Thalassemia Major. Hematology/Oncology and Stem Cell Therapy 2017; 10(4) doi: 10.1016/j.hemonc.2017.05.022
|
| 7 |
Irene Motta, Marta Mancarella, Alessia Marcon, Marco Vicenzi, Maria Domenica Cappellini. Management of age-associated medical complications in patients with β-thalassemia. Expert Review of Hematology 2020; 13(1) doi: 10.1080/17474086.2020.1686354
|
| 8 |
Khaled M. Musallam, Irene Motta, Marta Salvatori, Mirella Fraquelli, Alessia Marcon, Ali T. Taher, Maria Domenica Cappellini. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia. Blood Cells, Molecules, and Diseases 2012; 49(3-4) doi: 10.1016/j.bcmd.2012.06.001
|
| 9 |
Huang-Kai Peng, I-Ling Lin, Chien-Chih Lee, Li-Ya Wang, Cherng-Chyi Tzeng, Jan-Gowth Chang, Shyh-Chyun Yang. Synthesis and antitumor activity evaluation of anilinoquinoline derivatives by the effect on the expression of polo-like kinase. Medicinal Chemistry Research 2014; 23(3) doi: 10.1007/s00044-013-0749-3
|
| 10 |
Annita Kolnagou, Marios Kleanthous, George J. Kontoghiorghes. Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease. Frontiers in Bioscience-Elite 2022; 14(3) doi: 10.31083/j.fbe1403018
|
| 11 |
John C. Wood. Use of Magnetic Resonance Imaging to Monitor Iron Overload. Hematology/Oncology Clinics of North America 2014; 28(4) doi: 10.1016/j.hoc.2014.04.002
|
| 12 |
Andrea Mancuso, Giuseppe Butera, Margherita Rossi, Alberto Maringhini. Hepatocellular carcinoma in thalassemia and other hemoglobinopathies. Cancer 2023; 129(10) doi: 10.1002/cncr.34735
|
| 13 |
Andrea Mancuso. Management of hepatocellular carcinoma in thalassemia and importance of the human factor. Cancer 2017; 123(6) doi: 10.1002/cncr.30551
|
| 14 |
Joseph E. Maakaron, Maria Domenica Cappellini, Giovanna Graziadei, Jad Bou Ayache, Ali T. Taher. Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: A closer look at the role of siderosis. Annals of Hepatology 2013; 12(1) doi: 10.1016/S1665-2681(19)31397-3
|
| 15 |
Roberta D’Ambrosio, Erika Poggiali, Maria Domenica Cappellini. Treating hepatitis C in patients with hemoglobinopathies. Expert Opinion on Orphan Drugs 2015; 3(11) doi: 10.1517/21678707.2015.1086333
|
| 16 |
Current status of beta‐thalassemia and its treatment strategies. Molecular Genetics & Genomic Medicine 2021; 9(12) doi: 10.1002/mgg3.1788
|
| 17 |
Jung Wha Chung, Eun Shin, Haeryoung Kim, Ho‐Seong Han, Jai Young Cho, Young Rok Choi, Sukho Hong, Eun Sun Jang, Jin‐Wook Kim, Sook‐Hyang Jeong. Hepatic iron overload in the portal tract predicts poor survival in hepatocellular carcinoma after curative resection. Liver International 2018; 38(5) doi: 10.1111/liv.13619
|
| 18 |
Rayan Bou-Fakhredin, Irene Motta, Maria Domenica Cappellini, Ali T. Taher. Clinical Complications and Their Management. Hematology/Oncology Clinics of North America 2023; 37(2) doi: 10.1016/j.hoc.2022.12.007
|
| 19 |
Andrea Mancuso, Giovanni Perricone. Time to define a new strategy for management of hepatocellular carcinoma in thalassaemia?. British Journal of Haematology 2015; 168(2) doi: 10.1111/bjh.13098
|
| 20 |
Paul I. Tyan, Amr H. Radwan, Assaad Eid, Anthony G. Haddad, David Wehbe, Ali T. Taher. Novel Approach to Reactive Oxygen Species in Nontransfusion-Dependent Thalassemia. BioMed Research International 2014; 2014 doi: 10.1155/2014/350432
|
| 21 |
Andrea Mancuso. Management of hepatocellular carcinoma: Enlightening the gray zones. World Journal of Hepatology 2013; 5(6): 302-310 doi: 10.4254/wjh.v5.i6.302
|
| 22 |
Maher Malaeb, Ali T. Taher, Ala I. Sharara. Liver Cancer in the Middle East. 2021; doi: 10.1007/978-3-030-78737-0_23
|
| 23 |
Mohammad Hassan Hodroj, Ali Taher. Thalassemia and malignancies: Updates from the literature. Annals of the New York Academy of Sciences 2023; 1529(1) doi: 10.1111/nyas.15061
|
| 24 |
Antoine Finianos, Charbel F. Matar, Ali Taher. Hepatocellular Carcinoma in β-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis. International Journal of Molecular Sciences 2018; 19(12) doi: 10.3390/ijms19124070
|
| 25 |
Sevgi Özkaramehmet, Savanna Andreou, Kristia Yiangou, Soteroula Christou, Michalis Hadjigavriel, Maria Sitarou, Katerina Pyrovolaki, Eleni Papanicolaou, Christina Flourou, Irene Savvidou, Panagiotis Boutsikos, Alexandra Mendoni, Marina Kleanthous, Marios Phylactides, Carsten W. Lederer. Evaluation of Five Plasma miRNAs as Biomarkers for Minimally Invasive Staging of Liver Fibrosis in β-Thalassaemia Patients. International Journal of Molecular Sciences 2025; 26(19) doi: 10.3390/ijms26199543
|
| 26 |
Adriana Ceci, Laura Mangiarini, Fedele Bonifazi, Rossella Conte. Multidisciplinary Care in Haemoglobinopathies. Thalassemia Reports 2014; 4(3) doi: 10.4081/thal.2014.4875
|
| 27 |
Mohammad Hassan Hodroj, Rayan Bou-Fakhredin, Wared Nour-Eldine, Hussein A. Noureldine, Mohammad Hassan A. Noureldine, Ali T. Taher. Thalassemia and malignancy: An emerging concern?. Blood Reviews 2019; 37 doi: 10.1016/j.blre.2019.06.002
|
| 28 |
Silvia Fargion, Luca Valenti, Anna Ludovica Fracanzani. Role of iron in hepatocellular carcinoma. Clinical Liver Disease 2014; 3(5) doi: 10.1002/cld.350
|
| 29 |
Ashutosh Lal, Vip Viprakasit, Elliott Vichinsky, Yongrong Lai, Meng‐Yao Lu, Antonis Kattamis. Disease burden, management strategies, and unmet needs in α‐thalassemia due to hemoglobin H disease. American Journal of Hematology 2024; 99(11) doi: 10.1002/ajh.27440
|
| 30 |
João Arezes, Niall Foy, Kirsty McHugh, Doris Quinkert, Susan Benard, Anagha Sawant, Joe N. Frost, Andrew E. Armitage, Sant-Rayn Pasricha, Pei Jin Lim, May S. Tam, Edward Lavallie, Debra D. Pittman, Orla Cunningham, Matthew Lambert, John E. Murphy, Simon J. Draper, Reema Jasuja, Hal Drakesmith. Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia. Blood 2020; 135(8) doi: 10.1182/blood.2019003140
|
| 31 |
Samah F. Abozeid, Rasha A. Elkholy, Tamer A. Elbedewy, Mahmoud F. Seliem. Soluble fms-like tyrosine kinase-1 as a predictive marker for iron overload in adult patients with transfusion-dependent beta-thalassemia major. Tanta Medical Journal 2024; 52(3) doi: 10.4103/tmj.tmj_50_23
|
| 32 |
Andrea Mancuso. Evidence-based medicine and Management of Hepatocellular Carcinoma in Thalassemia. BMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01542-2
|
| 33 |
Racha Halawi, Irene Motta, Ali Taher, Maria Domenica Cappellini. Deferasirox: an orphan drug for chronic iron overload in non-transfusion dependent thalassemia syndromes. Expert Opinion on Orphan Drugs 2016; 4(6) doi: 10.1080/21678707.2016.1182018
|
| 34 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2016; doi: 10.1007/978-3-319-26587-2_165-1
|
| 35 |
Khaled M. Musallam, Maria D. Cappellini, John C. Wood, Ali T. Taher. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Reviews 2012; 26 doi: 10.1016/S0268-960X(12)70006-1
|
| 36 |
Hassan M. Moukhadder, Joseph E. Roumi, Rayan Bou-Fakhredin, Ali T. Taher. Hepatocellular Carcinoma in a β-Thalassemia Intermedia Patient: Yet Another Case in the Expanding Epidemic. Hemoglobin 2018; 42(1) doi: 10.1080/03630269.2018.1434197
|
| 37 |
Paschalis Paschos, Efthimia Vlachaki, Chrisoula Pasvanti, Emmanouil Sinakos, Anastasia Kalpaka, Philippos Klonizakis, Vasilios Perifanis. Safety and Efficacy of Combination Therapy with Pegylated Interferon Alpha-2a and Ribavirin in Treating Patients with Chronic Hepatitis C and Beta-Thalassaemia Major: A Greek Single-Center Experience. Acta Haematologica 2011; 126(4) doi: 10.1159/000330516
|
| 38 |
Christine C. Hsu, Nizar H. Senussi, Kleber Y. Fertrin, Kris V. Kowdley. Iron overload disorders. Hepatology Communications 2022; 6(8) doi: 10.1002/hep4.2012
|
| 39 |
Pierre Brissot, Olivier Loreal. Management of Liver Complications in Haemoglobinopathies. Thalassemia Reports 2014; 4(3) doi: 10.4081/thal.2014.4869
|